News Release

<< Back

SurModics to Webcast Fiscal 2006 First Quarter Earnings Conference Call January 25; Webcast is Live at 4:00 p.m. (CT)

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 18, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, today announced that it will host a live webcast of its fiscal 2006 first quarter conference call on Wednesday, January 25, at 4:00 p.m. CT. The company will issue an earnings news release after the market closes that afternoon.

Bruce Barclay, President and Chief Executive Officer, and Phil Ankeny, Chief Financial Officer and Vice President, Business Development, will recap the first quarter financial results and accomplishments. To access the webcast, go to the investor relations portion of the company's web site, www.surmodics.com, on the day of the conference call and click on the webcast icon.

An audio replay will be available beginning at 6:00 p.m. CT on Wednesday, January 25, until 6:00 p.m. CT on Wednesday, February 1 and can be accessed by dialing 800-405-2236 and entering conference call ID 11050823. In addition, the conference call audio will be archived on the company's web site following the call.

About SurModics, Inc.

SurModics, Inc. is a leading provider of surface modification technologies, in the areas of biocompatibility, site-specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of the SurModics' Bravo(TM) drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent and the use of CELLabration(TM) encapsulation system as an immunoprotective coating for implantable human islet cells. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.


    CONTACT: SurModics, Inc.
             Phil Ankeny, 952-829-2700

    SOURCE: SurModics, Inc.